Ares Management Corporation (NYSE: ARES) ("Ares"), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

The local sector of test makers, specialized equipment manufacturers and testing product suppliers remain invested in their ...

Tempus AI (NASDAQ: TEM) is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus ...

Ryan M. Bartolucci, the Chief Accounting Officer of Tempus AI , Inc. (NASDAQ:TEM), sold 6,059 shares of the company's Class A common stock on February 13, 2025. The timing is notable as TEM shares ...

There's still plenty of time for growth investors to click the buy button on Tempus AI stock; however, it's critical to ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...

Regarding the transaction, the lawmaker disclosed on January 14 the accumulation of 50 call options in Tempus AI with a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the ...

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...